United Therapeutics (NASDAQ:UTHR) CEO Sells $5,525,485.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $581.63, for a total transaction of $5,525,485.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $23,563,576.19. The trade was a 19.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Trading Down 1.0%

Shares of NASDAQ:UTHR traded down $5.46 during midday trading on Thursday, hitting $564.81. The stock had a trading volume of 830,972 shares, compared to its average volume of 495,835. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $607.89. The stock has a 50 day moving average price of $502.93 and a two-hundred day moving average price of $476.94. The company has a market capitalization of $24.76 billion, a PE ratio of 20.24, a P/E/G ratio of 1.72 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the previous year, the firm posted $6.19 EPS. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management increased its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of United Therapeutics during the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso IPF data remains the main bullish catalyst: the trial met its key endpoint, which drove a strong rally earlier this week and materially improves the drug’s commercial and pipeline upside. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Analyst support increased: HC Wainwright reiterated a Buy and raised some near‑term EPS estimates (and maintains a $660 price target), signaling confidence in the outlook after the clinical readout. This underpins further upside expectations. United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Unusually high options activity indicates elevated speculative/hedging interest — can amplify intraday moves but is ambiguous for longer‑term direction. Monitor open interest and whether activity is skewed to calls or puts. United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Mixed analyst/media coverage on valuation: some outlets are assessing upside given the Tyvaso win, while broader analyst surveys remain cautious/neutral — suggesting sentiment is mixed and price action may hinge on follow‑up commercial guidance and modeling. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Insider selling by the CEO and CFO: Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares on March 30 — sizable disposals that reduced their holdings materially and may be viewed negatively by some investors (though insiders sell for many reasons). SEC filings detail the transactions. SEC filing — Rothblatt sale SEC filing — Edgemond sale

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Finally, TD Cowen upped their price target on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $586.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.